AMP is WAC (and other thoughts)
Latest posts and updates
You can subscribe to AMP is WAC at https://apteka.substack.com/
ABOUT AMP is WAC
Average Manufacturer Price (AMP) is not equal to Wholesale Acquisition Cost (WAC), but it is close. And since the whole world of health policy and reimbursement is a bit WAC-y, that’s what we’re calling this update/blog part of the site. All of the opinions and thoughts presented here are our own and not the views of clients or affiliates.
-
Cell and Gene, CMMI, Drug shortages, DTC, FDA, Pharmacy Benefit Managers, State-based Reform, Supply Chain, Utilization ManagementAMP is WAC — 04/24/26
Read more: AMP is WAC — 04/24/26Stick a fork in me, I am done with this week. It was a busy week and then you add in a chief of staff (Eddie, the dog) that would whine every 2 hours at night to go outside to deal with a stomach issue and I’m toast. On one hand, #grateful, but ready for…
-
AMP is WAC — 04/10/26
Read more: AMP is WAC — 04/10/26Dam. What a few weeks. I Whistlered while I worked, but the avalanche of news has been hard to keep up with. (I mean, I found it funny.) If you’re interested, I’m hosting a free webinar on April 23 at 12 EST on Most Favored Nation. Quick 30-minute dive. Link to register is here: https://us06web.zoom.us/webinar/register/WN_iPlbMuS5RmeGSbcB8RSi-g…
-
Caught my eye, Cell and Gene, Drug Prices, DTC, Inflation Reduction Act, Medicare Part D, State-based Reform, UncategorizedAMP is WAC — 03/27/26
Read more: AMP is WAC — 03/27/26I’m supposed to be getting ready to take a few days off but I’m having trouble detaching. I’m so in the zone (and happy with it all) that the idea of stopping seems scary? Which absolutely means that I need to take a break, right?… No issue next week unless something big happens. Say Yes…
-
Affordable Care Act, Biosimilars, Drug Prices, DTC, Generics, Healthcare Costs, Medicaid, Utilization Management, VaccinesAMP is WAC — 03/20/26
Read more: AMP is WAC — 03/20/26What.a.week. The whirlwind of the Access conference, tons of pharmaceutical health policy news – and apparently a whole lot of new subscribers. Hi, welcome. Quick intro: I’m Jennifer Snow, I run Apteka Policy, 25 years in pharmaceutical health policy. I take the dense policy stuff – IRA negotiations, 340B fights, PBM reform – and tell…
-
340B, Affordable Care Act, Alzheimer’s, Biosimilars, Cell and Gene, CMMI, FDA, Inflation Reduction Act, Medicare Part D, ObesityAMP is WAC — 03/13/26
Read more: AMP is WAC — 03/13/26The Bigger They Are, the Faster They Grow. A new white paper from Health Capital Group, sponsored by Johnson & Johnson, analyzed HRSA’s OPAIS database from 2017 through 2023 and found something many observers of the 340B program have suspected for years; size is the dominant variable. Hospitals in the top quartile by bed size…
-
340B, Caught my eye, Drug Prices, Inflation Reduction Act, Medicaid, Medicare Part D, Pharmacy Benefit ManagersAMP is WAC — 3/6/26
Read more: AMP is WAC — 3/6/26Can you ever feel sad looking at photo of a chimp wearing clothes? Maybe it will make the latest policy news go down just a little smoother. 340B’s Split Screen. February 26 brought two developments in the 340B contract pharmacy fight. They pointed in opposite directions. First, a judge in the Middle District of Tennessee…
-
Caught my eye, Inflation Reduction Act, Medicare Advantage, Medicare Part D, Orphan Drugs, Pharmacy Benefit ManagersAMP is WAC — 02/27/26
Read more: AMP is WAC — 02/27/26Next week I’m joining Cencora for a webinar (sign up), followed by presenting at Access USA in Philadelphia and then, off to Vegas, for Asembia. If you’ll be in Philly or Vegas, I’d welcome a conversation about what’s truly consequential right now and what isn’t. Coffee or Paper Planes (IYKYK) optional. Quieter week around here…
-
340B, Biosimilars, Caught my eye, DTC, Employers, FDA, Obesity, Reference Pricing, State-based Reform, ValueAMP is WAC — 2/20/26
Read more: AMP is WAC — 2/20/26We have some new folks around these parts so quick intro. I’m Jennifer Snow. I’ve spent 25 years inside the U.S. pharmaceutical policy world, not watching it from the outside, but sitting in the meetings, reading the rules, and translating what they actually mean for the people whose drugs are on the line. I’m not…
-
340B, Affordable Care Act, Biosimilars, Caught my eye, Drug Prices, Inflation Reduction Act, Insulin, Medicare Negotiation, Medicare Part D, Pharmacy Benefit Managers, State-based Reform, Utilization ManagementAMP is WAC — 2/13/26
Read more: AMP is WAC — 2/13/26I chuckled during the E&C hearing when members were questioning the panelists about the pharmaceutical deals with the Administration. As if these are the people they should be asking. Make a left, make right, go down about a mile – there’s a big white house. Maybe they can help you there. Parallels Between 340B and…
-
Caught my eye, Copay Accumulators, Drug Prices, Employers, Healthcare Costs, Insulin, Medicare Part D, Pharmacy Benefit Managers, Utilization ManagementAMP is WAC — 2/6/26
Read more: AMP is WAC — 2/6/26No, I do not think that a groundhog is a meteorologist. But, one year I am determined to make it to see Punxsutawney Phil. I expect it to be silly and cold and over quickly. I will likely have to go solo because my family thinks getting a bus from a Wal-mart parking lot in…
Latest news
- AMP is WAC — 04/24/26
- AMP is WAC — 04/10/26
- AMP is WAC — 03/27/26
- AMP is WAC — 03/20/26
- AMP is WAC — 03/13/26
Categories
- 340B (64)
- Affordable Care Act (23)
- Alzheimer's (11)
- Biosimilars (33)
- Caught my eye (102)
- Cell and Gene (8)
- Chevron Deference (2)
- CMMI (29)
- Copay Accumulators (7)
- COVID (3)
- Drug Prices (58)
- Drug shortages (15)
- DTC (9)
- Employers (20)
- FDA (8)
- Generics (13)
- Health Equity (4)
- Healthcare Costs (41)
- Home Health (1)
- ICER (12)
- Importation (5)
- Inflation Reduction Act (69)
- Insulin (7)
- IP (3)
- Long term care (1)
- Medicaid (24)
- Medicare Advantage (27)
- Medicare Negotiation (68)
- Medicare Part D (78)
- Medicare Transaction Facilitator (5)
- Medicare Transaction Facilitator (12)
- Obesity (28)
- On the Horizon (1)
- Orphan Drugs (8)
- Pharmacy Benefit Managers (49)
- Preventative (5)
- Reference Pricing (26)
- State-based Reform (32)
- Supply Chain (8)
- Tariffs (2)
- Uncategorized (9)
- Utilization Management (14)
- Vaccines (10)
- Value (18)